Anand V Kulkarni
anandvkulkarni.bsky.social
Anand V Kulkarni
@anandvkulkarni.bsky.social
Hepatologist at AIG Hospitals, Hyderabad, India. Interests in ALD, ACLF & HCC
Reposted by Anand V Kulkarni
👨‍⚕️ @anandvkulkarni.bsky.social et al. reported that of the 156 patients with Wilson disease, pediatric patients more often presented as ALF/ACLF with lower TFS than adults. 54% of patients had pathogenic/likely pathogenic ATP7B variants.
🔗 ow.ly/YTUp50Xm89W
🏷️ #GITwitter #WilsonDisease
November 6, 2025 at 2:32 PM
With rising burden of metabolic diseases we are struggling with management of ascites in CKD. Here we try to answer them & provide an overview of approach to ascites in ESRD. @ebtapper.bsky.social @akashroyy.bsky.social

journals.lww.com/hepcomm/full...
Ascites in patients with end-stage renal disease:... : Hepatology Communications
d. However, patients with end-stage renal disease (ESRD) may also present with ascites even in the absence of cirrhosis. The literature on the management of patients with ESRD with ascites with or wit...
journals.lww.com
April 3, 2025 at 5:17 PM
Reposted by Anand V Kulkarni
Patients were randomized to FIT vs colonoscopy for colon cancer screening. Participation in any form of screening was 31.8% in the colonoscopy group and 39.9% in the FIT group. 10-year colon cancer mortality risk was 0.22% in colonoscopy arm and 0.24% in FIT arm.
www.thelancet.com/journals/lan...
Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial
Participation in screening was higher among individuals invited to faecal immunochemical test screening than colonoscopy screening. On the basis of participation observed in this study, a faecal immun...
www.thelancet.com
March 30, 2025 at 1:06 AM
A survey based study from AIG team and UoH on IT individuals who agreed to undergo tests
pubmed.ncbi.nlm.nih.gov/40128210/
>80% have fat in liver
20% have elevated liver enzymes
2% have fibrosis (advanced disease)
Fatty liver is curable with exercise (150 min/week) and healthy diet #Liversky
Prevalence of metabolic dysfunction-associated fatty liver disease among information technology employees in India - PubMed
The Information Technology (IT) sector is a leading industry that fuels India's economic growth. However, the work culture in this sector often promotes sedentary lifestyle, inadequate physical activi...
pubmed.ncbi.nlm.nih.gov
March 28, 2025 at 12:49 AM
The latest ACLF guidelines on harmonization of definition - steps from Asia. Joined by all the experts across the globe. Exhaustive recent updates and future directions.
@robbrierley.bsky.social @stevenbollipo.bsky.social @liveraim.bsky.social
link.springer.com/article/10.1...
Acute-on-chronic liver failure (ACLF): the ‘Kyoto Consensus’—steps from Asia - Hepatology International
Acute-on-chronic liver failure (ACLF) is a condition associated with high mortality in the absence of liver transplantation. There have been various definitions proposed worldwide. The first consensus...
link.springer.com
February 22, 2025 at 9:28 AM
Reposted by Anand V Kulkarni
📢Thrilled to share our latest review article. Greatful to Prof. Rakhi Maiwall. We explore challenges of managing septic shock in cirrhosis and advocate for personalized approaches
pubmed.ncbi.nlm.nih.gov/39744868/

#liversky #Medsky #GIsky

@anandvkulkarni.bsky.social
January 4, 2025 at 2:12 AM
Reposted by Anand V Kulkarni
There are *some* people whom steroids help

There is still value in trials, pragmatic trials, that refine inclusion criteria, dose, duration, and stopping rules

@anandvkulkarni.bsky.social
@juanpabloarab.bsky.social
@blaneymd.bsky.social
Steroids did not help people with alcohol-associated hepatitis in this nations cohort

doi.org/10.14309/ctg...

#liversky
December 12, 2024 at 1:11 PM
Reposted by Anand V Kulkarni
Congrats to inspiring investigators @anandvkulkarni.bsky.social @juanpabloarab.bsky.social and team, for late breaking abstract about rapid taper of steroids in AAH at #TLM24
⤵️ infections, hospitalizations with rapid taper
💫 changing practice in management of AAH
#LiverSky #AASLD
November 19, 2024 at 8:19 PM
Reposted by Anand V Kulkarni
Dose tapering reduced incidence of infection and use of antibiotics. No difference noted in survival #TLM24 #LiverSky
November 18, 2024 at 11:24 PM
Reposted by Anand V Kulkarni
Anand Kulkarni presents data from the STASH trial of dose tapering vs fixed dose corticosteroids in patients with severe alcohol-associated hepatitis #TLM24 #LiverSky
November 18, 2024 at 11:18 PM
Reposted by Anand V Kulkarni
This study by challenges dogma

@anandvkulkarni.bsky.social gave a tapering dose of prednisone for alcohol hepatitis instead of 40mg for 28 days

And it paid off with fewer infections

@tonybreu.bsky.social
November 18, 2024 at 11:42 PM
November 18, 2024 at 4:37 PM
Drugs for Mash cirrhosis by Prof Mazen Noureddin #TLM24
November 15, 2024 at 5:03 PM
Join to learn and discuss about Management of ACLF #Aasld #liversky
November 13, 2024 at 3:45 AM
Reposted by Anand V Kulkarni
I’ll be moderating a webinar tomorrow (Nov 13th) in conjunction with The Hepatitis Fund, as part of London Global Cancer Week 2024.

Join us to learn more on how liver cancer can be prevented via the elimination of viral hepatitis!

Register: us06web.zoom.us/webinar/regi...

#GastroSky #LiverSky
November 12, 2024 at 4:03 PM
Reposted by Anand V Kulkarni
Please put your info in your profile! It really helps decide who to follow
November 12, 2024 at 3:47 PM
Dr Tapper cares not only for patients but for liver and GI docs. Thank you so much for this- Very useful #liversky @ebtapper.bsky.social
Sharing #gisky and #liversky

Will add to it by end of day

Let me know and I will update

go.bsky.app/8Pho2tp
November 12, 2024 at 2:23 AM
Reposted by Anand V Kulkarni
So fun seeing all of my #livertwitter (🪦❔) friends now on #LiverSky (and IRL #TLM24)
November 12, 2024 at 1:42 AM